1. Home
  2. PMAX vs NXTS Comparison

PMAX vs NXTS Comparison

Compare PMAX & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PMAX

Powell Max Limited

HOLD

Current Price

$2.00

Market Cap

3.7M

Sector

N/A

ML Signal

HOLD

NXTS

Nexentis Technologies Inc. Common Stock

N/A

Current Price

$5.34

Market Cap

3.7M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
PMAX
NXTS
Founded
2019
2009
Country
Hong Kong
Israel
Employees
53
9
Industry
Agricultural Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
3.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PMAX
NXTS
Price
$2.00
$5.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
213.6K
44.1K
Earning Date
05-12-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.55
52 Week High
$5.20
$6.75

Technical Indicators

Market Signals
Indicator
PMAX
NXTS
Relative Strength Index (RSI) 45.13 50.58
Support Level $1.70 $4.13
Resistance Level $2.87 $5.77
Average True Range (ATR) 0.30 0.82
MACD -0.06 -0.03
Stochastic Oscillator 28.18 25.43

Price Performance

Historical Comparison
PMAX
NXTS

About PMAX Powell Max Limited

Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.

About NXTS Nexentis Technologies Inc. Common Stock

Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.

Share on Social Networks: